Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 13/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 3/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173555 | 0.92 | IGF1R (0.41) | IGF1RTACR1PDE2A | |
| SCHEMBL6173419 | 0.91 | IGF1R (0.42) | IGF1RTACR1PDE2A | |
| SCHEMBL6173461 | 0.90 | IGF1R (0.39) | IGF1RTACR1PDE2A | |
| SCHEMBL6178301 | 0.87 | EPHX2 (0.41) | — | |
| SCHEMBL6175941 | 0.87 | PTGS2 (0.39) | IGF1RTACR1SMN1; SMN2 | |
| SCHEMBL6174941 | 0.85 | IGF1R (0.45) | IGF1RPDE2A | |
| SCHEMBL6174717 | 0.85 | IGF1R (0.54) | IGF1RPDE2A | |
| SCHEMBL6173502 | 0.85 | IGF1R (0.38) | IGF1R | |
| SCHEMBL17558356 | 0.83 | IGF1R (0.56) | IGF1RPDE2A | |
| SCHEMBL6174371 | 0.81 | IGF1R (0.44) | IGF1RPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599464-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004070050-A2 | CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | WO | disclosed |